@CaliLerone @PopsWhisky @mattkolleck1 @Nina_kd @d_stock07734 From this: ''The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS).'' https://t.co/n6nL0iLpc7 They ran a randomised trial. The idea is to sho
@smith348572 As a matter of fact, all the C-suite of $NVCR started selling after the first results on DCVax-L were published on May 29, 2018. https://t.co/HxvuSsItHE
RT @AXuring2: @Longing4L @hoffmann6383 Way higher indeed! Don't forget that $NWBO's SP prior to May 10 was already at an artificially suppr…
RT @AXuring2: @Longing4L @hoffmann6383 Way higher indeed! Don't forget that $NWBO's SP prior to May 10 was already at an artificially suppr…
RT @AXuring2: @Longing4L @hoffmann6383 Way higher indeed! Don't forget that $NWBO's SP prior to May 10 was already at an artificially suppr…
@Longing4L @hoffmann6383 Way higher indeed! Don't forget that $NWBO's SP prior to May 10 was already at an artificially suppressed level. Suppressed by thieves! We've had nothing but good news for YEARS (at least since 2018). Good news is supposed to corre
The first results of the same trial reported in 2018 had primary end point as PFS and secondary end point as OS. The article now has change of primary end point and inclusion of external control to bring in conclusions for the clinical benefit 6/n https:
@patrickwalsh14 @BIO99_BIO99 @metacollectiveG @mabbpah @DocOck222 @apwriter I think this therapy works though. I believe in a subset of patients with characteristics that have been described, e.g., methylated MGMT patients https://t.co/kkImstrWND
@BLawenda @oncology_bg @AshleySumrallMD @EKNduom @VickersBiostats @JAMAOnc Great thanks! I'll listen later when I have some time. The missing ITT analysis unfortunately wasn't in a prior publication either. I'll see if that comes up in the discussion. I ho
@cancerphysicist @matthwilliams @subatomicdoc @ProfAJChalmers @oncology_bg @AshleySumrallMD @EKNduom @VickersBiostats @JAMAOnc Please find interim results as follows:- https://t.co/ZHXk5lpreT
@cancerphysicist @matthwilliams @ProfAJChalmers @oncology_bg @AshleySumrallMD @EKNduom @VickersBiostats @JAMAOnc It looks like number of screened patients listed in this prior publication HT to @hammymo22. All patients' results reported but not separated b
@GoodPoint123 They did wait...2018 interm analysis showing basically what we saw in JAMA. Still the #CitadelScandal kept SP down in an attempt to bankrupt $NWBO. $0.14-$0.39....FOR 4 years even with breaking interm results. So yes they had to raise capit
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
RT @alphavestcap: https://t.co/3gurIQFxAq $nwbo @alphavestcap
RT @alphavestcap: https://t.co/3gurIQFxAq $nwbo @alphavestcap
https://t.co/3gurIQFxAq $nwbo @alphavestcap
RT @DawnAnnManning: $nwbo
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
$nwbo
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
RT @sharpie510: Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication.…
Dr. Andrew Sloan: "SYM05B-Brain Tumor Update" Oct 8, 2022. He is a co-author of the #DCVax-L First Results P3 publication. https://t.co/xdr5VzwdU8 The DCVax® Platform For All Solid Tumor Cancers $nwbo #glioblastoma #cancer #vaccine $mrk $bmy $rhhby $pfe
@MC17595091 Where's the evidence -- it wasn't in the original trial protocol (only for Naive GBM). Show the evidence instead of just saying so. Read Dr. Liau's peer review article from 2018 -- NO identification of a crossover - 10 years after trial start
@ritz245552 @Arhdan9 Dr. Liau, the lead investigator published this paper, a decade into the trial: https://t.co/FzIkaNVqUQ. Then look at the $NWBO updated (May 2022) protocol, endpoints and comparator @ https://t.co/gSO2uUFO55 https://t.co/TAMwRTD0Qi.
RT @biosectinvestor: So Adam Feuerstein's allegations of unblinding, along with those of the shorts, would necessarily involve a massive co…
So Adam Feuerstein's allegations of unblinding, along with those of the shorts, would necessarily involve a massive conspiracy of all of the doctors who are signatories to this study, a very unlikely circumstance. https://t.co/Zqygzi37u1
RT @KnowWhatYouHold: @WojciechSmann2 @sharpie510 $NWBO - In summary, Joel has received a full treatment cycle of DCVax and shows no signs o…
RT @eastvillagetwt: Dr. Mulholland is listed in the Phase 3 interim results just before the CTO Marnix Bosch, in the below article: $NWBO…
$NWBO #MOASS
RT @eastvillagetwt: Dr. Mulholland is listed in the Phase 3 interim results just before the CTO Marnix Bosch, in the below article: $NWBO…
Dr. Mulholland is listed in the Phase 3 interim results just before the CTO Marnix Bosch, in the below article: $NWBO #DCVaxL https://t.co/PO8PPtUW1f
@tradrjoze This data, from 2018, really 2017, because it took a long time to gather the interim data, but published then, is the data from her presentations. And there may have been, from time to time, older data from other arms that were long ago PR'd/pu
RT @eastvillagetwt: Impressive interim data from 2018 Journal article, still blinded, has been noted by numerous other third-party journal…
Impressive interim data from 2018 Journal article, still blinded, has been noted by numerous other third-party journal articles. First results on survival from a large Phase 3 clinical trial #DCVaxL $NWBO https://t.co/PO8PPtUobH
@sharpie510 Just stinks this isnt any new news as it is from 2018 results. Refreshing old content https://t.co/q1u5aZFInH
@SodApOpPIMPski https://t.co/J2LB10Mhbd Cmon now, you're not really this dumb are you?🤣 https://t.co/G4fKy2njpM
RT @mariali94316534: https://t.co/1QdQZ1oTrF First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell…
@SodApOpPIMPski @justinkeister5 Interim results and conclusion of P3!... https://t.co/uVPL8Su0p1
RT @sharpie510: Dr. Cloughesy is one of the co-authors of the $NWBO #DCVax-L interim results for #glioblastoma in the Journal of Translatio…
"Beneficial effects of immune therapies are often observed at later time points, in the tail of the survival curve...it appears that patients who survive past certain threshold time points may continue onwards to unusually long survival times..." $nwbo htt
Why are early results like these in the JTM buried while results for COVID vaccines touted for efficacy? Will final published data lead to a massive change in sentiment? https://t.co/VFg1Kx5YSf
@SnackBioTech @justinkeister5 @DynastyAssets But I expect results, at the very least, consistent with those published previously and likely better, since those results included the placebo... https://t.co/Zqygzi37u1 That is certainly not "hidden".
RT @alphavestcap: ON THIS 5/15/21 PODCAST DR.ASHKAN UPDATED THE 6/1/18 Translational paper on the blinded DC VAX trial. 100 best GBM p…
RT @alphavestcap: ON THIS 5/15/21 PODCAST DR.ASHKAN UPDATED THE 6/1/18 Translational paper on the blinded DC VAX trial. 100 best GBM p…
ON THIS 5/15/21 PODCAST DR.ASHKAN UPDATED THE 6/1/18 Translational paper on the blinded DC VAX trial. 100 best GBM patients living 7-8 years .https://t.co/jYYKzDbenU https://t.co/BYogOUXX8T @alphavestcap https://t.co/k1tz2WfvvB $nwbo
@talltexanrealty @Jordongf2 @cloutiernico 2018: Interim report on efficacy of DCVax-L https://t.co/uVPL8Su0p1
RT @Arhdan9: @jimcramer @US_FDA $NWBO's DCVax-L shows significant improvement in OS https://t.co/h6OoGGy12K over the current standard of ca…
RT @Arhdan9: @jimcramer @US_FDA $NWBO's DCVax-L shows significant improvement in OS https://t.co/h6OoGGy12K over the current standard of ca…
RT @Arhdan9: @jimcramer @US_FDA $NWBO's DCVax-L shows significant improvement in OS https://t.co/h6OoGGy12K over the current standard of ca…
RT @Arhdan9: @BillAckman @US_FDA $NWBO has published blinded data showing significant improvement https://t.co/h6OoGGy12K over current stan…
RT @Arhdan9: @jimcramer @US_FDA $NWBO's DCVax-L shows significant improvement in OS https://t.co/h6OoGGy12K over the current standard of ca…
@jimcramer @US_FDA $NWBO's DCVax-L shows significant improvement in OS https://t.co/h6OoGGy12K over the current standard of care https://t.co/YCJBWynzOd. Since SOC has had no improvement over the past decades the improvement can only contribute to DCVax-L!
@BillAckman @US_FDA $NWBO has published blinded data showing significant improvement https://t.co/h6OoGGy12K over current standard of carehttps://www.ncbi.nlm.nih.gov/books/NBK469987/ which it can be seen SOC has almost no improvement over the past decades
RT @Arhdan9: Sorry the publication showing significant OS data from DCVax-L trial over SOC is https://t.co/h6OoGGgqbc, but the publication…
Sorry the publication showing significant OS data from DCVax-L trial over SOC is https://t.co/h6OoGGgqbc, but the publication initially cited does show no improvement of SOC for decades.
RT @KnowWhatYouHold: @WojciechSmann2 @sharpie510 $NWBO - In summary, Joel has received a full treatment cycle of DCVax and shows no signs o…
@WojciechSmann2 @sharpie510 $NWBO - In summary, Joel has received a full treatment cycle of DCVax and shows no signs of tumor progression. Joel's body is responding favorably to this treatment as many patients have in the DCVax-L trial as per the 2018 inte
RT @rago_carlo: @TheBigLong2019 @SchlangDaddy Linda Liau at a SNO meeting, for example, updates to the interim data published below https…
@NwboScam You’re not attacking all the doctors and institutions that signed onto this interim, still blinded journal report on #DCVaxL results from a few years ago, with spectacular results. https://t.co/Zqygzi37u1
@TheBigLong2019 @SchlangDaddy Linda Liau at a SNO meeting, for example, updates to the interim data published below https://t.co/2YXWpw4z8N
RT @sharpie510: Dr. Cloughesy is one of the co-authors of the $NWBO #DCVax-L interim results for #glioblastoma in the Journal of Translatio…
$NWBO #DCVAX
RT @sharpie510: Dr. Cloughesy is one of the co-authors of the $NWBO #DCVax-L interim results for #glioblastoma in the Journal of Translatio…
RT @sharpie510: Dr. Cloughesy is one of the co-authors of the $NWBO #DCVax-L interim results for #glioblastoma in the Journal of Translatio…
Dr. Cloughesy is one of the co-authors of the $NWBO #DCVax-L interim results for #glioblastoma in the Journal of Translational Medicine. 58.4 months mOS for the top 100 patients!💪 The DCVax® Platform For All Solid Tumor Cancers https://t.co/ApO8HAV0Tq
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
RT @sharpie510: @TiltMyBrain SNO starts November 18, 2021. At least 12 co-authors of the $NWBO #DCVax-L Phase 3 blinded article published i…
RT @sharpie510: @TiltMyBrain SNO starts November 18, 2021. At least 12 co-authors of the $NWBO #DCVax-L Phase 3 blinded article published i…
RT @sharpie510: @TiltMyBrain SNO starts November 18, 2021. At least 12 co-authors of the $NWBO #DCVax-L Phase 3 blinded article published i…
@TiltMyBrain SNO starts November 18, 2021. At least 12 co-authors of the $NWBO #DCVax-L Phase 3 blinded article published in the JTM are registered as "Conference Speakers".🤞😉 $mrk $bmy $rhhby The DCVax® Platform For All Solid Tumor Cancers https://t.co/
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
Previously released, still blinded results from 2017/18: https://t.co/yZ42oT5ddg
RT @KnowWhatYouHold: To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is un…
To anyone that is losing confidence in $NWBO please just glance over these interim results again from 2018. This is unfiltered, documented blinded data. Nothing has changed, in fact they've likely gotten better due to long term survivors: https://t.co/o6Ps
@woodman267 @Hmblchino21 https://t.co/aymuygePTT. At the contrary, the likelihood of success is extremely high
RT @eastvillagetwt: #DCVaxL $NWBO “This article is in the 99th percentile (ranked 104th) of the 292,882 tracked articles of a similar age…
RT @eastvillagetwt: $NWBO #DCVaxL Top Line Data Phase 3 pending #GBM #Glioblastoma #CancerVaccine for solid tumors Earlier Blinded Results…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
RT @sharpie510: 26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWB…
26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021 12 co-authors from the $NWBO #DCVax-L JTM paper listed as "Conference Speakers". #glioblastoma $mrk $bmy #sno2021 The DCVax® Platform https://t.co/ApO8HAV0Tq
@doveinhand 4) about Mesenchymal gene expressions responding well right about at the 22 minute mark. A different method of differentiating who will respond to the vaccine is an article from the Journal of Translational Medicine. https://t.co/MIRsZWWlDl. It
RT @eastvillagetwt: #DCVaxL $NWBO “This article is in the 99th percentile (ranked 104th) of the 292,882 tracked articles of a similar age…